drugset
drugset / Trial / NCT05149560

Ticagrelor Monotherapy After Stenting

NCT05149560 ↗

Phase 2 Completed 200 enrolled Vastra Gotaland Region Sahlgrenska University Hospital · collab
NaSingle-groupOpen-labelTreatment

Summary

A pilot study planned to evaluate initial safety of ticagrelor monotherapy after coronary stenting due to acute myocardial infarction. The study is a single-centre, single-arm, prospective phase II study 200 patients who undergo coronary artery stenting due to NSTEMI or STEMI will be included. Primary endpoint (variable): The composite of cardiac death, spontaneous myocardial infarction or definite or probable stent thrombosis within 3 months.

Timeline

Start
2021-12-14
Primary completion
2025-06-26
Completion
2025-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Ticagrelor Small molecule 90 mg —

Indications

acute myocardial infarction